Please assess the completion status of the following clinical trial:

Trial Title: AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria for rheumatoid arthritis classification (1987 revision) or the 2010 ACR-EULAR (The European League Against Rheumatism) classification criteria for rheumatoid arthritis~Exclusion Criteria:~* Functional class IV according by the ACR revised classification (1991)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab 6 months (Type: EXPERIMENTAL): denosumab administered subcutaneously every 6 months
- Denosumab 3 months (Type: EXPERIMENTAL): denosumab administered subcutaneously every 3 months
- placebo (Type: PLACEBO_COMPARATOR): placebo administered subcutaneously to match denosumab

Based on this trial design, predict the completion outcome and termination type (if applicable).